Alexander Röntgen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Alexander Röntgen has a total of 49 co-authors. Here are the top co-authors by number of shared publications:
- Michele Vendruscolo
Centre for Misfolding Diseases, Yusuf Hamied Department of Chemistry, University of Cambridge, Cambridge, UK
5 shared publications - Zenon Toprakcioglu
Centre for Misfolding Diseases, Yusuf Hamied Department of Chemistry, University of Cambridge
4 shared publications - Adeola Shobo
Department of Pharmacology and Therapeutics, McGill University, Montreal, Quebec, Canada
2 shared publications - Gerhard Multhaup
Department of Pharmacology and Therapeutics, McGill University, Montreal, Quebec, Canada; Integrated Program in Neuroscience, McGill University, Montreal, Quebec, Canada
2 shared publications - Mark A. Hancock
Department of Pharmacology and Therapeutics, McGill University, Montreal, Quebec, Canada
2 shared publications Alfonso De Simone
Department of Pharmacy, University of Naples Federico II, Naples 80131, Italy
1 shared publication
Latest Publications
- Open Access
Melanin Suppresses Aβ Aggregation and Toxicity
The aggregation of amyloid-β (Aβ) peptides into insoluble deposits is a characteristic hallmark of Alzheimer’s disease (AD) and related neurodegenerative disorders. While AD is the most common cause of dementia, there are currently no disease-modifying treatments which are both affordable and adverse-free. In this study, we report that melanin, a pigment which is commonly found in nature and is abundant in parts of the human brain, suppresses the aggregation of the 42-amino acid Aβ variant (Aβ42). Using biophysical and biochemical techniques, we show that melanin delays Aβ42 aggregation while also reducing the amount of Aβ42 that converts into aggregates. Using thioflavin T assays paired with chemical kinetics, we characterised the melanin-induced inhibition of Aβ42 aggregation in vitro. Using MALDI-MS, we elucidate the molecular basis of this effect by showing that melanin prevents Aβ42 dimerisation. We then demonstrate that melanin also reverts the aggregation process by dissolving pre-formed Aβ42 fibrils. Finally, we show that melanin reduces Aβ42 aggregation and rescues Aβ42 toxicity in an SH-SY5Y neuroblastoma cell model. Our study shows that melanin disrupts the aggregation and cytotoxicity of Aβ42, and suggests that compounds derived from human metabolites may offer promising avenues to combat amyloid formation.
Open AccessMelanin Suppresses Aβ Aggregation and Toxicity
The aggregation of amyloid-β (Aβ) peptides into insoluble deposits is a characteristic hallmark of Alzheimer’s disease (AD) and related neurodegenerative disorders. While AD is the most common cause of dementia, there are currently no disease-modifying treatments which are both affordable and adverse-free. In this study, we report that melanin, a pigment which is commonly found in nature and is abundant in parts of the human brain, suppresses the aggregation of the 42-amino acid Aβ variant (Aβ42). Using biophysical and biochemical techniques, we show that melanin delays Aβ42 aggregation while also reducing the amount of Aβ42 that converts into aggregates. Using thioflavin T assays paired with chemical kinetics, we characterised the melanin-induced inhibition of Aβ42 aggregation in vitro. Using MALDI-MS, we elucidate the molecular basis of this effect by showing that melanin prevents Aβ42 dimerisation. We then demonstrate that melanin also reverts the aggregation process by dissolving pre-formed Aβ42 fibrils. Finally, we show that melanin reduces Aβ42 aggregation and rescues Aβ42 toxicity in an SH-SY5Y neuroblastoma cell model. Our study shows that melanin disrupts the aggregation and cytotoxicity of Aβ42, and suggests that compounds derived from human metabolites may offer promising avenues to combat amyloid formation.
- Open Access
Low-abundance αSyn-112 promotes αSyn-140 aggregation in vitro and forms immunoreactive deposits in Parkinson’s disease brain tissue
The aggregation of α-synuclein (αSyn) is a molecular hallmark of Parkinson’s disease (PD) and other synucleinopathies. Understanding the molecular mechanisms that determine the aggregation of this protein may thus facilitate the development of disease-modifying therapies. While αSyn is most commonly expressed as a 140-residue protein (αSyn-140), recent evidence suggests an involvement of alternatively spliced αSyn isoforms in disease onset and progression. Here, we report and characterise the interaction between αSyn-140 and the aggregation-prone αSyn-112 variant, one of the most abundant αSyn splice isoforms. We found that amounts as low as 1% of αSyn-112 accelerate the nucleation and aggregation of αSyn-140. To further investigate this phenomenon, we employed MALDI-MS and NMR spectroscopy, confirming that αSyn-140 and αSyn-112 monomers interact strongly with one another. Furthermore, to assess the association of αSyn-112 with disease pathology, we performed immunohistochemical staining combined with confocal microscopy on PD brain samples. Thereby, we found an increase in the number as well as the area of αSyn-112 immunoreactive aggregates compared to healthy controls. These results illustrate how low-abundance αSyn splice isoforms can modulate the aggregation landscape of αSyn-140 and in turn contribute to the molecular heterogeneity of synucleinopathies.
Open AccessLow-abundance αSyn-112 promotes αSyn-140 aggregation in vitro and forms immunoreactive deposits in Parkinson’s disease brain tissue
The aggregation of α-synuclein (αSyn) is a molecular hallmark of Parkinson’s disease (PD) and other synucleinopathies. Understanding the molecular mechanisms that determine the aggregation of this protein may thus facilitate the development of disease-modifying therapies. While αSyn is most commonly expressed as a 140-residue protein (αSyn-140), recent evidence suggests an involvement of alternatively spliced αSyn isoforms in disease onset and progression. Here, we report and characterise the interaction between αSyn-140 and the aggregation-prone αSyn-112 variant, one of the most abundant αSyn splice isoforms. We found that amounts as low as 1% of αSyn-112 accelerate the nucleation and aggregation of αSyn-140. To further investigate this phenomenon, we employed MALDI-MS and NMR spectroscopy, confirming that αSyn-140 and αSyn-112 monomers interact strongly with one another. Furthermore, to assess the association of αSyn-112 with disease pathology, we performed immunohistochemical staining combined with confocal microscopy on PD brain samples. Thereby, we found an increase in the number as well as the area of αSyn-112 immunoreactive aggregates compared to healthy controls. These results illustrate how low-abundance αSyn splice isoforms can modulate the aggregation landscape of αSyn-140 and in turn contribute to the molecular heterogeneity of synucleinopathies.
- Open Access
- 9 March 2026
- Published by Wiley in Applied Research
- Vol. 5 (2)
Rational Design of Nanobodies Targeting LINGO‐1
The leucine‐rich repeat and immunoglobulin‐like domain‐containing Nogo receptor‐interacting protein 1 (LINGO‐1) is a transmembrane protein expressed in neurons and oligodendrocytes. Since LINGO‐1 is involved in the regulation of axonal outgrowth and neuronal survival as well as oligodendrocyte differentiation and axon myelination, it has been investigated as a potential drug target for demyelinating diseases such as multiple sclerosis. In this study, we implement a pipeline to generate and test single‐domain antibodies (nanobodies) targeting the functionally relevant immunoglobulin‐like (Ig‐like) domain of LINGO‐1 using an in‐silico design method. First, we designed complementarity‐determining region 3 (CDR3) loops and grafted them onto a suitable nanobody scaffold. We then recombinantly expressed the designed nanobodies in bacteria followed by purification using liquid chromatography. Next, after characterising the purity and structural integrity of the produced nanobodies, we validated their binding to LINGO‐1 using an enzyme‐linked immunosorbent assay (ELISA). Overall, the strategy that we employed in this study provides a framework for the generation of nanobodies against challenging targets based on in‐silico design methods followed by testing to identify suitable candidates.
- 9 March 2026
- Published by Wiley in Applied Research
- Vol. 5 (2)
Open AccessRational Design of Nanobodies Targeting LINGO‐1
The leucine‐rich repeat and immunoglobulin‐like domain‐containing Nogo receptor‐interacting protein 1 (LINGO‐1) is a transmembrane protein expressed in neurons and oligodendrocytes. Since LINGO‐1 is involved in the regulation of axonal outgrowth and neuronal survival as well as oligodendrocyte differentiation and axon myelination, it has been investigated as a potential drug target for demyelinating diseases such as multiple sclerosis. In this study, we implement a pipeline to generate and test single‐domain antibodies (nanobodies) targeting the functionally relevant immunoglobulin‐like (Ig‐like) domain of LINGO‐1 using an in‐silico design method. First, we designed complementarity‐determining region 3 (CDR3) loops and grafted them onto a suitable nanobody scaffold. We then recombinantly expressed the designed nanobodies in bacteria followed by purification using liquid chromatography. Next, after characterising the purity and structural integrity of the produced nanobodies, we validated their binding to LINGO‐1 using an enzyme‐linked immunosorbent assay (ELISA). Overall, the strategy that we employed in this study provides a framework for the generation of nanobodies against challenging targets based on in‐silico design methods followed by testing to identify suitable candidates.
- Open Access
- 26 July 2025
- Published by Wiley in FEBS Letters
- Vol. 599 (19) , 2750-2767
Aβ42 promotes the aggregation of α‐synuclein splice isoforms via heterogeneous nucleation
Increasing evidence suggests that amyloid‐β (Aβ) and α‐synuclein (αSyn) co‐aggregate in Alzheimer's disease (AD) and Parkinson's disease (PD), an in other neurodegenerative disorders. We investigated how Aβ42 – the predominant Aβ form in AD – co‐aggregates with four αSyn splice isoforms (αSyn‐140, αSyn‐126, αSyn‐112 and αSyn‐98) implicated in PD, finding evidence of a two‐step process. Aβ42 first aggregated into fibrillar assemblies, which then acted as potent nucleation surfaces for initiating the aggregation of αSyn isoforms. Furthermore, pre‐formed Aβ42 seeds promoted αSyn aggregation more strongly than in situ Aβ42 aggregates. Our results reveal a unified Aβ–αSyn co‐aggregation mechanism, where Aβ aggregation and αSyn splicing synergistically drive co‐deposition. These findings could help develop therapeutic tools to target key steps in disease‐related co‐aggregation pathways. Impact statement: By demonstrating that Aβ42 fibril seeds serve as potent heterogeneous nucleation surfaces for four common α‐synuclein splice isoforms, this study mechanistically links protein aggregation in Alzheimer's and Parkinson's diseases. Kinetic analysis identifies early cross‐seeding events, suggesting intervention points to delay mixed amyloid pathologies in neurodegeneration.
- 26 July 2025
- Published by Wiley in FEBS Letters
- Vol. 599 (19) , 2750-2767
Open AccessAβ42 promotes the aggregation of α‐synuclein splice isoforms via heterogeneous nucleation
Increasing evidence suggests that amyloid‐β (Aβ) and α‐synuclein (αSyn) co‐aggregate in Alzheimer's disease (AD) and Parkinson's disease (PD), an in other neurodegenerative disorders. We investigated how Aβ42 – the predominant Aβ form in AD – co‐aggregates with four αSyn splice isoforms (αSyn‐140, αSyn‐126, αSyn‐112 and αSyn‐98) implicated in PD, finding evidence of a two‐step process. Aβ42 first aggregated into fibrillar assemblies, which then acted as potent nucleation surfaces for initiating the aggregation of αSyn isoforms. Furthermore, pre‐formed Aβ42 seeds promoted αSyn aggregation more strongly than in situ Aβ42 aggregates. Our results reveal a unified Aβ–αSyn co‐aggregation mechanism, where Aβ aggregation and αSyn splicing synergistically drive co‐deposition. These findings could help develop therapeutic tools to target key steps in disease‐related co‐aggregation pathways. Impact statement: By demonstrating that Aβ42 fibril seeds serve as potent heterogeneous nucleation surfaces for four common α‐synuclein splice isoforms, this study mechanistically links protein aggregation in Alzheimer's and Parkinson's diseases. Kinetic analysis identifies early cross‐seeding events, suggesting intervention points to delay mixed amyloid pathologies in neurodegeneration.
- Open Access
- 18 April 2025
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 11 (16) , eadq5396
Aggregation of α-synuclein splice isoforms through a phase separation pathway
The aggregation of α-synuclein (αSyn) is associated with Parkinson’s disease and other related synucleinopathies. Considerable efforts have thus been directed at understanding this process. However, the recently discovered condensation pathway, which involves the formation of phase-separated liquid intermediate states, has added further complexity. In parallel, it has been reported that different αSyn splice isoforms may be implicated in aggregate formation in disease. In this study, we compare the phase behavior of four αSyn isoforms (αSyn-140, αSyn-126, αSyn-112, and αSyn-98). Using different biophysical tools including confocal microscopy, kinetic assays and microfluidic-based approaches, we find stark differences between the four systems in their propensities to undergo phase separation and aggregation. Furthermore, we show that even small amounts of αSyn-112, one of the predominant isoforms after αSyn-140, can affect the phase separation of αSyn-140. These results highlight the importance of conducting further investigations to elucidate the role of alternative splicing in synucleinopathies.
- 18 April 2025
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 11 (16) , eadq5396
Open AccessAggregation of α-synuclein splice isoforms through a phase separation pathway
The aggregation of α-synuclein (αSyn) is associated with Parkinson’s disease and other related synucleinopathies. Considerable efforts have thus been directed at understanding this process. However, the recently discovered condensation pathway, which involves the formation of phase-separated liquid intermediate states, has added further complexity. In parallel, it has been reported that different αSyn splice isoforms may be implicated in aggregate formation in disease. In this study, we compare the phase behavior of four αSyn isoforms (αSyn-140, αSyn-126, αSyn-112, and αSyn-98). Using different biophysical tools including confocal microscopy, kinetic assays and microfluidic-based approaches, we find stark differences between the four systems in their propensities to undergo phase separation and aggregation. Furthermore, we show that even small amounts of αSyn-112, one of the predominant isoforms after αSyn-140, can affect the phase separation of αSyn-140. These results highlight the importance of conducting further investigations to elucidate the role of alternative splicing in synucleinopathies.
- 7 October 2024
- Published by Wiley in BioFactors
- Vol. 51 (1)
Preface
- Open Access
The diversity of SNCA transcripts in neurons, and its impact on antisense oligonucleotide therapeutics
Summary: The role of the SNCA gene locus in driving Parkinson’s disease (PD) through rare and common genetic variation is well-recognized, but the transcriptional diversity of SNCA in vulnerable cell types remains unclear. We performed SNCA long-read RNA sequencing in human dopaminergic neurons and show that annotated SNCA transcripts account for only 5% of expression. Rather, the majority of expression (75%) at the SNCA locus originates from transcripts with alternative 5’ and 3’ untranslated regions. Importantly, 10% originates from transcripts encoding open reading frames not previously annotated, which are translated and detectable in human postmortem brain. Defining the 3’ untranslated regions enabled the rational design of antisense oligonucleotides targeting the majority of SNCA transcripts, leading to the effective reversal of PD pathology, including protein aggregation, mitochondrial dysfunction, and toxicity. Resolving the complexity of the SNCA transcriptional landscape impacts RNA therapies and highlights differences in protein isoforms and their contribution to disease.
Open AccessThe diversity of SNCA transcripts in neurons, and its impact on antisense oligonucleotide therapeutics
Summary: The role of the SNCA gene locus in driving Parkinson’s disease (PD) through rare and common genetic variation is well-recognized, but the transcriptional diversity of SNCA in vulnerable cell types remains unclear. We performed SNCA long-read RNA sequencing in human dopaminergic neurons and show that annotated SNCA transcripts account for only 5% of expression. Rather, the majority of expression (75%) at the SNCA locus originates from transcripts with alternative 5’ and 3’ untranslated regions. Importantly, 10% originates from transcripts encoding open reading frames not previously annotated, which are translated and detectable in human postmortem brain. Defining the 3’ untranslated regions enabled the rational design of antisense oligonucleotides targeting the majority of SNCA transcripts, leading to the effective reversal of PD pathology, including protein aggregation, mitochondrial dysfunction, and toxicity. Resolving the complexity of the SNCA transcriptional landscape impacts RNA therapies and highlights differences in protein isoforms and their contribution to disease.
- 2 November 2023
- Published by Springer Nature
Open AccessSDS-PAGE v1
Protocol for running an SDS-PAGE.
- Open Access
- 2 November 2023
- Published by Springer Nature
Cell culture v1
Protocol to culture SH-SY5Y cells.
- 2 November 2023
- Published by Springer Nature
Open AccessCell culture v1
Protocol to culture SH-SY5Y cells.